NASDAQ:FLDM - Fluidigm Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.20 +0.45 (+5.81 %)
(As of 11/19/2018 02:25 AM ET)
Previous Close$8.20
Today's Range$7.60 - $8.33
52-Week Range$4.65 - $8.62
Volume266,064 shs
Average Volume407,430 shs
Market Capitalization$322.45 million
P/E Ratio-6.89
Dividend YieldN/A
Beta2.84
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

Receive FLDM News and Ratings via Email

Sign-up to receive the latest news and ratings for FLDM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:FLDM
Previous Symbol
CUSIP34385P10
Phone650-266-6000

Debt

Debt-to-Equity Ratio7.56
Current Ratio1.85
Quick Ratio1.45

Price-To-Earnings

Trailing P/E Ratio-6.89
Forward P/E Ratio-8.28
P/E GrowthN/A

Sales & Book Value

Annual Sales$101.94 million
Price / Sales3.16
Cash FlowN/A
Price / CashN/A
Book Value$0.57 per share
Price / Book14.39

Profitability

EPS (Most Recent Fiscal Year)($1.19)
Net Income$-60,530,000.00
Net Margins-50.46%
Return on Equity-86.00%
Return on Assets-11.01%

Miscellaneous

Employees505
Outstanding Shares39,320,000
Market Cap$322.45 million
OptionableOptionable

Fluidigm (NASDAQ:FLDM) Frequently Asked Questions

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) announced its quarterly earnings data on Thursday, November, 1st. The medical research company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.20. The medical research company had revenue of $28.96 million for the quarter, compared to the consensus estimate of $27.50 million. Fluidigm had a negative return on equity of 86.00% and a negative net margin of 50.46%. View Fluidigm's Earnings History.

When is Fluidigm's next earnings date?

Fluidigm is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Fluidigm.

What price target have analysts set for FLDM?

1 analysts have issued 1-year target prices for Fluidigm's stock. Their forecasts range from $6.10 to $6.10. On average, they expect Fluidigm's share price to reach $6.10 in the next twelve months. This suggests that the stock has a possible downside of 25.6%. View Analyst Price Targets for Fluidigm.

What is the consensus analysts' recommendation for Fluidigm?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fluidigm.

Has Fluidigm been receiving favorable news coverage?

News stories about FLDM stock have been trending positive on Monday, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Fluidigm earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future.

Who are some of Fluidigm's key competitors?

Who are Fluidigm's key executives?

Fluidigm's management team includes the folowing people:
  • Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 45)
  • Mr. Vikram Jog, CFO & Principal Accounting Officer (Age 62)
  • Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 44)
  • Mr. Steven C. McPhail, Chief Commercial Officer (Age 64)
  • Ms. Mai Chan Yow, MD of Fluidigm Singapore Pte Ltd & EVP of Worldwide Manufacturing - Fluidigm Singapore Pte Ltd (Age 59)

Who are Fluidigm's major shareholders?

Fluidigm's stock is owned by many different of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (14.89%), Neuberger Berman Group LLC (11.53%), Russell Investments Group Ltd. (10.91%), BlackRock Inc. (5.01%), Renaissance Technologies LLC (2.93%) and Acadian Asset Management LLC (1.22%). Company insiders that own Fluidigm stock include Evan/ Fa Jones, Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Institutional Ownership Trends for Fluidigm.

Which major investors are selling Fluidigm stock?

FLDM stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., BlackRock Inc., TIAA CREF Investment Management LLC, Panagora Asset Management Inc. and Los Angeles Capital Management & Equity Research Inc.. View Insider Buying and Selling for Fluidigm.

Which major investors are buying Fluidigm stock?

FLDM stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Primecap Management Co. CA, JPMorgan Chase & Co., JPMorgan Chase & Co., Acadian Asset Management LLC, Perkins Capital Management Inc., Neuberger Berman Group LLC and Campbell & CO Investment Adviser LLC. Company insiders that have bought Fluidigm stock in the last two years include Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Insider Buying and Selling for Fluidigm.

How do I buy shares of Fluidigm?

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fluidigm's stock price today?

One share of FLDM stock can currently be purchased for approximately $8.20.

How big of a company is Fluidigm?

Fluidigm has a market capitalization of $322.45 million and generates $101.94 million in revenue each year. The medical research company earns $-60,530,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fluidigm employs 505 workers across the globe.

What is Fluidigm's official website?

The official website for Fluidigm is http://www.fluidigm.com.

How can I contact Fluidigm?

Fluidigm's mailing address is 7000 Shoreline Court Suite 100, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000.


MarketBeat Community Rating for Fluidigm (NASDAQ FLDM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  417 (Vote Outperform)
Underperform Votes:  248 (Vote Underperform)
Total Votes:  665
MarketBeat's community ratings are surveys of what our community members think about Fluidigm and other stocks. Vote "Outperform" if you believe FLDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel